Movers explained · September 15, 2026

Why Is VERA THERAPEUTICS IN A (VERA) Stock Moving Today?

By the Top Tier Newswire AI Desk · August 14, 2026 at 9:41 AM ET · reviewed against 5 wire stories

VERA THERAPEUTICS IN A (VERA) is drawing unusual attention today. Our newswire has captured 5 stories on VERA across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Why VERA stock is up today

VERA stock is up 10.64% to $31.96 in today’s session, driven by positive developments related to the FDA review of its kidney disease therapy. The stock opened with a 9.4% gap up and traded as high as $37.24 before retreating. The move follows recent analyst activity and better-than-expected earnings in the second quarter.

What Happened

Vera Therapeutics shares surged after the FDA completed its review of the company’s therapy for kidney disease. This regulatory update is seen as a key milestone in the drug’s development timeline. The stock’s performance was also supported by recent earnings, where the company reported a Q2 EPS of $(1.52), which beat the $(1.61) estimate. Analysts from multiple firms have maintained or adjusted their ratings in recent weeks, with several maintaining Buy ratings and adjusting price targets. These include HC Wainwright & Co., TD Cowen, Guggenheim, and Wedbush.

What The Data Shows

The stock opened at $31.62, reflecting a significant gap up from the previous close of $28.89. Trading reached an intraday high of $37.24 at 7:30 AM ET before pulling back to a low of $29.73 at 9:30 AM ET. The session volume of 1.4 million shares is 90% above the 3-month daily average. The stock currently trades within its 52-week range of $21.04 to $56.05. With a market cap of $2.3 billion and an unprofitable earnings profile (TTM EPS -5.57), the stock remains a speculative play.

What To Watch

Vera Therapeutics has not announced upcoming earnings, but investors may watch for further analyst coverage and regulatory updates regarding its kidney disease therapy. The stock’s volatility and analyst activity suggest continued interest in the company’s pipeline.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

VERA by the numbers

Coverage: 5 stories / 5 sourcesAI sentiment: 63/100 (bullish)Mkt cap: $2.3B52w: $21.04 to $56.05

VERA · Aug 14 session (5-min) · +9.58% vs prior close · updated 8:49 PM ET

AI sentiment, last 36h · averaged over 5 stories · 63/100 bullish

The headlines behind the move

Story flow · 5 stories on the wire, last 36h · hover or tap a dot for the headline

38m agoThe FlyBULLISH 67General

Vera Therapeutics up 13% in pre-market at $38.63 after trutakna ORIGIN 3 data

56m agoSeeking AlphaBULLISH 73Product/PR

Vera set for full FDA approval of Trutakna after late-stage trial win

Vera Therapeutics (VERA) stock jumps as the firm posts a late-stage trial win for its lead asset Trutakna in primary IgA nephropathy, a kidney disease. Read more here.

59m agoInvesting.com MarketsNEUTRAL 50General

Why is Vera Therapeutics stock surging today?

1h agoSEC 8-KNEUTRAL 50General

Vera Therapeutics, Inc. (VERA) files 8-K

Filed: 2026-09-15 AccNo: 0001193125-26-391280 Size: 11 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

1h agoBusiness InsiderBULLISH 73Product/PR

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite...

Frequently asked questions

Why is VERA stock moving today?

VERA THERAPEUTICS IN A (VERA) is drawing unusual attention today. Our newswire has captured 5 stories on VERA across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100). The most recent driver: "Vera Therapeutics up 13% in pre-market at $38.63 after trutakna ORIGIN 3 data" (The Fly).

Is VERA a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of VERA coverage reads 63/100 over 5 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.

More moves explained today

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on VERA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.